Core Insights - Intensity Therapeutics (INTS.US) announced significant results from its Phase 1/2 clinical trial for the candidate drug INT230-6, leading to a nearly 395% surge in stock price [1] Group 1: Drug Mechanism and Clinical Data - INT230-6 operates by directly injecting into tumors, facilitating the diffusion of cisplatin and vinblastine sulfate, along with a cell-penetrating enhancer molecule (SHAO) [1] - The trial involved 64 patients across over 20 cancer types, all of whom had undergone extensive prior treatments, achieving a disease control rate of 75% [1] - The median overall survival (mOS) for the entire patient group was 11.9 months, with a notable 21.3 months for the metastatic sarcoma subgroup [1] - No grade 4 or 5 treatment-related adverse events were reported, with only 7 patients experiencing grade 3 adverse events, and no dose-limiting toxicities observed [1] Group 2: Market Reaction and Future Plans - The market reacted positively to the trial data, indicating strong interest in the field of solid tumor treatments [2] - Intensity Therapeutics has partnered with Merck (MRK.US) and Bristol-Myers Squibb (BMY.US) to explore combination therapies with Keytruda and Yervoy [2] - A conference call is scheduled for October 31 to discuss the clinical trial results, which have been published in the journal eBioMedicine [2]

Group 1 - Anna Van Acker, the President of Merck China, will transition to a strategic management role in the Human Health Division after her four-year tenure in China [1] - Under her leadership, Merck China launched 36 new products and indications, benefiting over 20 million people in 2024 [1] - Kyle Tattle, the current President of Merck Japan, will succeed Anna Van Acker as the President of Merck China, bringing extensive experience in oncology and market growth [1] Group 2 - Merck reported total revenue of $64.168 billion for 2024, a 7% year-on-year increase, with pharmaceutical revenue at $57.4 billion, also up 7% [2] - Revenue from the Chinese market declined by 20% to $5.394 billion, accounting for 9.4% of Merck's global pharmaceutical business [2] - Keytruda (pembrolizumab) remains the primary revenue source, generating $29.482 billion with an 18% growth, representing approximately 45.95% of total revenue [2] Group 3 - Merck's HPV vaccine, Gardasil/Gardasil 9, achieved sales of $8.583 billion in 2024, a 3% decline primarily due to reduced demand in China, offset by growth in other international markets [2] - The nine-valent HPV vaccine received approval for new indications for males aged 16-26, marking a significant advancement in HPV prevention in China [3] - Merck is committed to talent development and organizational capability building to support its strategic implementation in China [3]